Skip to content

MELINTA THERAPEUTICS, INC. /NEW/

CIK 0001461993

← back to feed
Revenue (TTM)
$79.99M
+4.1% YoY Q3 Nov 2019
Net Income (TTM)
−$303.95M
−58.4% YoY Q3 Nov 2019
EPS Diluted (TTM)
—
Q3 Nov 2019
Gross Margin
53.0%
Q3 Nov 2019
Operating Margin
-348.3%
Q3 Nov 2019
Net Margin
-380.0%
Q3 Nov 2019
Free Cash Flow (TTM)
−$116.24M
Q3 Nov 2019
Cash
$63.52M
Q3 Nov 2019
Total Debt
$10.35M
Q3 Nov 2019
Shares Outstanding
13.75M sh
Q3 Nov 2019

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings